Benzodiazepines Rapid Test Cassette,
Urine Sample Rapid Test Cassette,
BZO rapid diagnostic kit
Benzodiazepines (BZO) Rapid Test is a rapid, screening test for the qualitative detection of Benzodiazepines (BZO)and metabolites in human urine at specified cut off levels.
For professional use only.
For in vitro diagnostic use only.
【INTENDED USE OF BENZODIAZEPINES(BZO) RAPID TEST】
Rapid Benzodiazepines (BZO) Test is an immuno-chromatographic assay for the qualitative determination of the presence of Benzodiazepines (BZO) listed in the table below.
This assay provides only a preliminary analytical test result. Gas Chromatography/Mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to Benzodiazepines (BZO) of abuse test result, particularly when preliminary positive results are indicated.
Benzodiazepines are a class of drugs that are often therapeutically used as anxiolytics, anti-convulsants and sedative hypnotics. Benzodiazepines manifest their presence by analgesia, drowsiness, confusion, diminished reflexes, lowering of body temperature, respiratory depression, blockade of adrenocortical response, and a decrease in peripheral resistance without an impact on the cardiac index. The major pathways of elimination are the kidneys (urine) and the liver where it is conjugated to glucuronic acid. Large doses of Benzodiazepines could develop tolerances and physiological dependency and lead to its abuse. Only trace amounts (less than 1%) of Benzodiazepines are excreted unaltered in the urine, most of Benzodiazepines in urine is conjugated drug. Oxazepam, a common metabolite of many benzodiazepines, remains detectable in urine for up to one week, which makes Oxazepam a useful marker of Benzodiazepines abuse.
【PRINCIPLE OF BENZODIAZEPINES(BZO) RAPID TEST】
Benzodiazepines (BZO) Rapid Test is a competitive immunoassay that is used to screen for the presence of Benzodiazepines (BZO) and metabolites in urine. It is chromatographic absorbent device in which, drugs within a urine sample, competitively combined to a limited number of drug monoclonal antibody (mouse) conjugate binding sites.
When the test is activated, the urine is absorbed into test by capillary action, mixes with the respective drug monoclonal antibody conjugate, and flows across a pre-coated membrane. When drug within the urine sample is below the detection level of the test, respective drug monoclonal antibody conjugate binds to the respective drug-protein conjugate immobilized in the Test Region (T) of the test . This produces a colored Test line in the Test Region (T) of the Test, which, regardless of its intensity, indicates a negative test result.
When sample drug levels are at or above the detection level of the test, the free drug in the sample binds to the respective drug monoclonal antibody conjugate,
preventing the respective drug monoclonal antibody conjugate from binding to the respective drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a preliminary positive result.
To serve as a procedure control, a colored line will appear at the Control Region (C) of Test, if the test has been performed properly.
【WARNINGS AND PRECAUTIONS】
【STORAGE AND STABILITY】
【INTERPRETATION OF RESULTS】
Preliminary positive (+)
Only one colored band appears, in the control region (C). No colored band appears in the test region (T).
Two colored bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region (T).
Control band fails to appear. Results from any test which has not produced a control band at the specified read time must be discarded. Please review the procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.